Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02963311 · ClinicalTrials.gov registry record · Phase 2
A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
A Phase 2 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02963311: Completed Phase 2 study, sponsored by The Medicines Company.
NCT02963311 is a Phase 2 study that has completed, run by The Medicines Company. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02963311, a Phase 2 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of ALN-PCSSC in participants with homozygous familial hypercholesterolemia.
Primary Outcome
Due to the small number of subjects, and the fact that the data are not normally distributed, the data are presented as descriptive statistics with no inferential and limited summary statistics presented.
Interventions
- DRUG Standard of Care
- DRUG ALN-PCSSC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-12-13 |
| Est. Completion | 2018-10-08 |
| Phase | Phase 2 |
What the finished NCT02963311 record still lists
NCT02963311 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT02963311 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02963311 about?
NCT02963311 is a clinical study titled "A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)". The purpose of this study is to assess the safety, tolerability, and efficacy of ALN-PCSSC in participants with homozygous familial hypercholesterolemia.
What is the current status of trial NCT02963311?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2016-12-13. Estimated completion is 2018-10-08.
What interventions are being tested in trial NCT02963311?
The interventions under investigation include: Standard of Care (DRUG), ALN-PCSSC (DRUG).
Who is sponsoring clinical trial NCT02963311?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02963311's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI